Impacting approximately one-third of the U.S. population, obesity is a significant health concern for Americans. It’s a risk factor for developing type 2 diabetes, heart disease, and certain forms of cancer, and now, according to an article published in the January/February 2013 issue of General Dentistry, the peer-reviewed clinical journal of the Academy of General [ Read More ]
New analysis by the charity Diabetes UK expects the number of people in Britain with diabetes to rise by 700,000 by the end of the decade. This indicates 4.4 million people in the UK alone by 2020. The majority of new cases are predominantly expected to be Type 2 diabetes. People who develop Type 2 [ Read More ]
New study connects the cancer gene Lin28 to glucose metabolism; may shed light on unifying principles in type 2 diabetes A pathway activated in cancer plays an unexpected key role in metabolic diseases like type 2 diabetes, according to a study by researchers at Children’s Hospital Boston. Evidence that the Lin28/let-7 pathway influences the cellular [ Read More ]
Increased low-grade inflammation in the body resulting from obesity is widely viewed as contributing to type 2 diabetes. Going against this long-held belief, researchers from Children’s Hospital Boston report that two proteins activated by inflammation are actually crucial for maintaining good blood sugar levels – and that boosting the activity of these proteins can normalize [ Read More ]
Treating Diabetes With Less Need for Insulin Diabetes can result from either a deficiency of insulin (type 1 or insulin-dependent diabetes) or decreased sensitivity to insulin (type 2 diabetes). Â Researchers at Children’s Hospital Boston have discovered a mechanism for normalizing blood sugar that doesn’t involve insulin and could offer a new therapeutic approach to both [ Read More ]
Arena Pharmaceuticals and Eisai Inc. reported that top-line results from the one-year lorcaserin BLOOM-DM trial demonstrate statistically significant weight loss in obese and overweight patients with type 2 diabetes. In this trial, lorcaserin met all three co-primary efficacy endpoints. In addition, as described below, lorcaserin patients taking lorcaserin 10 mg twice daily (BID) achieved statistically [ Read More ]